ArticleAnnals of nuclear medicine2026
The role of 18 F-FDG PET/CT SUVmax values in evaluating treatment response in hormone receptor-positive metastatic breast cancer patients receiving CDK4/6 inhibitor therapy.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMetastatic breast cancer is a disease with poor prognosis. For many years, it has been treated with endocrine therapy; however, due to the promising results of CDK 4/6 inhibitors, their combination with endocrine therapy has recently become an essential component of metastatic breast cancer treatment. Although no standardized approach exists for evaluating the response to CDK 4/6 inhibitors, assessment with 18 F-FDG PET/CT may be possible. In this study, we aimed to assess the treatment response using 18 F-FDG PET/CT SUVmax values in hormone receptor-positive metastatic breast cancer patients receiving CDK 4/6 inhibitors.
methodsOur study was designed as a single-center, retrospective analysis including 94 patients (93 females, 1 male). The mean age at diagnosis was 55 years. The most commonly used treatment combination was ribociclib + letrozole (45.7%). Neutropenia was the most frequent adverse event associated with CDK 4/6 inhibitors (35.5% of patients), followed by fatigue (25.8%) and nausea (19.4%).
resultsThe mean highest SUVmax value (primary tumor + metastases) before CDK4/6 inhibitor treatment was 11.20, which decreased to 7.32 after treatment initiation (p = 0.001). Patients with a marked absolute reduction in SUVmax (AUC: 0.769, p = 0.001, cut-off: 3.35) had longer progression-free survival (PFS) compared with those without a reduction (28.92 months vs. 14.47 months). The difference between pre- and post-treatment SUVmax values was significantly associated with both Clinical Benefit Rate (CBR) and Objective Response Rate (ORR) (p = 0.001).
conclusionEarly changes in 18 F-FDG PET/CT SUVmax values can serve as a valuable predictive marker for treatment response and survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.
Indexed as
Identifiers
42213275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.